Loading clinical trials...
Loading clinical trials...
The objective is to demonstrate the non-inferiority of T2769 compared to Hylo-Forte® in terms of the change from baseline (D1) in total ocular surface staining score assessed on Oxford 0-15 scale, in ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Laboratoires Thea
NCT06220474 · Dry Eye Syndromes, Meibomian Gland Dysfunction
NCT07412860 · Dry Eye Syndromes, Dry Eye Disease (DED)
NCT07295691 · Autologous Serum Eye Drops, Dry Eye Syndrome
NCT03135327 · Multiple Sclerosis, Dry Eye Syndromes, and more
NCT02585414 · Dry Eye Syndromes
OFTEX, s.r.o.
Prague
Axon Clinical, s.r.o.
Prague
Ganglion Medical Center
Pécs, Baranya
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions